Cell and Gene Outsourcing

  1. Improved And Rebalanced Plasmids To Ramp Up Your AAV Productivity

    Growth in rAAV-based therapies is creating a need for dramatically increased production. Learn how AAV productivity can be optimized using platform technologies capable of affording significantly higher titers.

  2. Industry-Leading Lentiviral Titers Through Optimized Production Technology 8/28/2023

    See how VirusExpress' technology was optimized to provide industry-leading lentiviral titer and a streamlined approach to accelerate development timelines and de-risk manufacturing.

  3. Combining Expertise With Best-In-Class Technology 10/20/2021

    Members of the MilliporeSigma leadership team reflect on the longstanding experience of our BioReliance® viral vector manufacturing facilities. Our legacy experience, alongside our brand new facility and latest industry innovations, ensure we are a preferred partner to pioneer the path to cures.

  4. Manufacturing Life-Saving Gene Therapies 2/24/2021

    Take a look behind the scenes and hear firsthand about the commitment to patients and clients at Andelyn Biosciences.

  5. An Early Formulation Screening Service 5/23/2024

    Gain insights into overcoming the challenges in lipid nanoparticle (LNP) formulation, explore critical aspects of the process and analytical development of LNPs, and much more.

  6. Navigating The Road To Gene Therapy Commercialization 8/27/2020

    With increases in development and investments in the gene therapy field, companies will increasingly be looking at manufacturing and commercialization of their therapies. Road to commercialization goes through a series of process validation phases. In this webinar, we take a closer look at the road to commercialization and focus on addressing primary questions.

  7. Early Developability And Analytical Toolbox For The Production Of Multi-Chain Biotherapeutics

    In recent years, the number of biotherapeutic molecules requiring more complex assemblies has greatly increased. Typically, these multi-chain molecules are no longer compatible with platform approaches and require a more agile approach to early developability and method development.

  8. The Journey To Safety Through Viral Clearance 12/1/2022

    Discover a simple yet powerful solution for getting viral clearance studies done safely, thoroughly, efficiently, and on your timelines. Learn how to free your teams and trust your project.

  9. Candidate Screening And Feasibility Studies For Viral Gene Therapies

    Create a simple, modular path to cGMP manufacturing that minimizes risk. Explore a strategic approach for early-stage development and how it can propel therapies to the clinic and the market.

  10. Accelerate Development And De-Risk Gene Therapy Manufacturing 10/20/2023

    Join viral vector process and analytical development experts as they showcase strategies for developing robust processes and analytics for efficient and de-risked manufacturing.